CBER and EMA CAT — Regulatory Differences That Shape Your Global GT CMC Strategy

A gene therapy CMC package optimized for CBER will not automatically satisfy the EMA’s Committee for Advanced Therapies. The differences are not cosmetic — they are substantive enough to require a deliberate dual-region strategy.

Most gene therapy programs that plan simultaneous or sequential FDA and EMA submissions treat the two dossiers as parallel tracks requiring only format translation. That assumption is wrong, and it is most expensive when discovered at pre-submission rather than pre-IND. The regulatory frameworks governing these two jurisdictions were constructed on different statutory foundations, enforced by committees with different scientific mandates, and operationalized through guidance documents that diverge at the level of starting material definition, adventitious agent testing methodology, and the mechanistic expectations placed on potency assays. A program that aligns its CMC strategy to only one of these frameworks before Phase I is not running a lean development program — it is deferring a structural rework that will cost time, batch material, and submission cycles at the worst possible moment.

The CBER Jurisdiction and Review Process for Gene Therapy: How It Differs From CDER and EMA CAT

Within FDA, gene therapy products are regulated by the Center for Biologics Evaluation and Research under the Office of Tissues and Advanced Therapies, not CDER — a distinction with direct CMC consequences. CBER/Office of Therapeutic Products (OTP) reviewers apply a biologics framework that treats the vector, the manufacturing process, and the finished drug product as an integrated biological system rather than a drug substance defined solely by its chemical structure. The foundational submission reference for IND CMC packages is FDA’s Chemistry, Manufacturing, and Controls Information for Human Gene Therapy INDs (2020), which establishes the expectation that characterization data generated during development serve as the evidentiary basis for lot release specifications — but does not treat those two categories as equivalent. CBER reviewers routinely issue deficiencies when sponsors submit characterization data formatted as release specifications without the underlying process knowledge that justifies the specification limits.

The IND review framework under 21 CFR Part 1271 imposes additional requirements for cellular and tissue-based products that often apply to ex vivo gene therapy constructs, requiring donor eligibility screening and communicable disease testing that are not automatically aligned with EMA’s donor testing requirements under Directive 2004/23/EC. For systemic AAV products, the CBER CMC review specifically addresses dose-related safety considerations that have no direct structural analogue in EMA guidance. Onasemnogene abeparvovec (Zolgensma, BLA 125694, approved 2019) established CBER’s precedent for systemic IV administration of AAV at a dose of 1.1×1014 vg/kg — the highest approved systemic AAV dose — and CBER’s post-approval requirements included hepatotoxicity and thrombotic microangiopathy monitoring, as well as ongoing CMC stability data through five years post-approval. The pre-IND Type B meeting process that CBER uses to align CMC expectations before IND submission has no structural equivalent in EMA’s scientific advice procedure in terms of the specificity of CMC commitments it can generate.

For CNS-directed programs using intrathecal or intracerebroventricular delivery, CBER applies a stricter endotoxin threshold of ≤0.06 EU/mL — ten times more stringent than the standard IV limit — and requires artificial CSF-compatible formulation justification. FDA’s guidance document “Human Gene Therapy for Rare Diseases” (2020) specifically addresses dose-related neurotoxicity considerations including dorsal root ganglion toxicity observed in NHP GLP toxicology studies at high systemic AAV doses, establishing a CMC-toxicology linkage that reviewers will trace through from the preclinical package to the clinical dosing specification.

The EMA Committee for Advanced Therapies (CAT): Mandate, Review Procedure, and CMC Expectations

The EMA’s Committee for Advanced Therapies was established under EU Regulation 1394/2007 on Advanced Therapy Medicinal Products as the scientific committee responsible for the evaluation of ATMPs — a product category that encompasses gene therapy medicinal products, somatic cell therapy products, and tissue-engineered products. The CAT’s jurisdiction is defined by the ATMP classification, which determines not only which regulatory pathway applies but which starting material requirements govern the dossier. This matters for CMC because EU Regulation 1394/2007 and the implementing Annex I of Directive 2001/83/EC impose specific requirements for the characterization and documentation of starting materials — including viral vector production plasmids, producer cell lines, and any biological materials of human or animal origin — that must appear explicitly in Module 3 and be addressed in Module 2.

The EMA/CAT Guideline on quality, non-clinical and clinical aspects of gene therapy medicinal products (EMA/CAT/80183/2014) establishes that potency assays for gene therapy products must demonstrate a mechanistic link to the claimed mode of action — not merely reflect transduction efficiency or transgene copy number. This is a higher standard than the functional potency assay accepted under some CBER IND submissions, where surrogate assays with justified correlation to biological activity have been accepted in early clinical stages. A program that develops a potency assay calibrated to CBER’s phased development expectations may arrive at EMA’s scientific advice process with an assay that satisfies the CBER reviewer but does not meet CAT’s mechanistic linkage requirement — generating a development commitment at the Phase II/III boundary that requires cell-based assay qualification work in parallel with clinical execution.

EMA/CAT guidance specific to gene therapy medicinal products — read alongside EMA’s ATMP comparability Q&A document — further addresses comparability exercise expectations that differ from ICH Q5E in meaningful ways. ICH Q5E provides the general biologics comparability framework, but the CAT Reflection Paper applies that framework specifically to GT products in ways that require additional attention to vector genome integrity, full/empty capsid ratio comparability, and the biological activity bridging criteria that define an acceptable comparability outcome. A program that plans its comparability protocol exclusively against ICH Q5E without incorporating CAT-specific expectations may reach a manufacturing change that CBER accepts under comparability but that CAT requires additional clinical bridging to close.

The Key CMC Differences Between a CBER BLA and an EMA ATMP Dossier

The most operationally significant difference between a CBER BLA and an EMA ATMP MAA at the CMC level is the starting material documentation requirement. Under Annex I of Directive 2001/83/EC, the ATMP dossier must provide a complete characterization of all starting materials, including the viral vector production plasmids and producer cell substrates, with traceability to source documentation and adventitious agent testing results that satisfy Ph. Eur. requirements. Ph. Eur. 5.1.7, the European Pharmacopoeia general chapter on viral safety, specifies testing methods and acceptance criteria for adventitious agents that are not identical to USP or FDA-aligned testing strategies. A program that has completed its viral safety evaluation using FDA-aligned in vitro and in vivo adventitious agent testing protocols will typically need to assess whether those protocols include the specific virus panels and testing conditions required under Ph. Eur. 5.1.7 — and the answer is frequently no, generating an analytical gap that must be closed with additional testing on archived samples or future manufacturing runs.

Adventitious agent testing is not the only divergence. The WHO Expert Committee on Biological Standardization guidelines for gene therapy products introduce an international reference standard framework that EMA reviewers may invoke during MAA review when assessing quantitative assay alignment, particularly for vector genome titer by ddPCR and capsid titer by ELISA. A program using ddPCR ITR-targeting for genome titer and Progen PRATV ELISA for capsid quantification needs to evaluate whether its assay calibration is traceable to international reference materials in a way that a CAT reviewer would find scientifically justified — not merely whether the assay is internally validated. The full/empty capsid ratio determined by analytical ultracentrifugation sedimentation velocity, reported as a sedimentation coefficient from AUC-SV, must be justified against specifications that EMA reviewers may assess differently than CBER — particularly regarding the acceptable range and the batch data supporting it.

The practical consequence for dual-region programs is that a CMC package built solely to CBER BLA standards will encounter structural deficiencies at EMA MAA review in three predictable areas: starting material characterization under Annex I, adventitious agent testing methodology under Ph. Eur. 5.1.7, and potency assay mechanistic linkage under EMA/CAT/80183/2014. None of these deficiencies are resolvable by reformatting — they require additional laboratory work, testing, and in some cases assay development. Programs that discover this at pre-submission are facing a six- to eighteen-month remediation cycle at a stage when clinical timelines are already under pressure.

Building a Dual-Region GT CMC Strategy That Satisfies Both CBER and EMA CAT Without Duplicate Programs

The XGene GT Dual-Region CMC Gap Assessment is a structured side-by-side evaluation of CBER and EMA CAT requirements applied to a program’s existing CMC package, designed to identify jurisdiction-specific gaps before they generate deficiency letters or submission delays.

Step 1 — Jurisdiction Classification and Starting Material Mapping. Confirm the product’s ATMP classification under EU Regulation 1394/2007 and map every starting material — including production plasmids, producer cell substrates, and any human- or animal-derived raw materials — against both 21 CFR Part 1271 requirements and Annex I of Directive 2001/83/EC. This step surfaces documentation gaps that are invisible when the dossier is assessed against only one regulatory framework and that, if unresolved, generate Module 3 deficiencies regardless of clinical data quality.

Step 2 — Adventitious Agent Testing Protocol Side-by-Side Review. Compare the existing viral safety evaluation protocol against both FDA-aligned testing strategy and Ph. Eur. 5.1.7 requirements, identifying any virus panels, testing conditions, or in vivo safety study designs present in one protocol but absent from the other. This step determines whether archived samples from existing manufacturing runs can close the gap or whether prospective testing on future batches is required — a decision that directly affects manufacturing and clinical timelines.

Step 3 — Potency Assay Mechanistic Linkage Assessment. Evaluate the current potency assay against EMA/CAT/80183/2014’s requirement for demonstrated mechanistic linkage to mode of action, assessing whether the assay design — including cell line selection, readout parameter, and acceptance criteria — satisfies CAT’s standard or only CBER’s phased-development surrogate assay acceptance. For CNS programs, this includes evaluating whether the neuronal cell line used in the potency assay (NSC-34, primary motor neurons, or iPSC-derived motor neurons) is scientifically justified for both jurisdictions.

Step 4 — Comparability Protocol Dual-Region Calibration. Review any planned or completed comparability studies against both ICH Q5E and EMA’s ATMP-specific comparability guidance, specifically assessing whether full/empty capsid ratio comparability criteria, vector genome integrity bridging, and biological activity acceptance criteria are sufficient for CAT review or are calibrated only to ICH Q5E’s general biologics standard.

The output of the XGene GT Dual-Region CMC Gap Assessment is a jurisdiction-mapped remediation matrix that classifies each identified gap by regulatory basis, resolution pathway, and timeline impact — not a general compliance checklist, but a submission-ready gap-close plan that tells the CMC team exactly what laboratory work, documentation, and module updates are required before each filing.

A gene therapy program that arrives at EMA pre-submission with a CBER-optimized CMC package is not facing a formatting problem — it is facing a scientific remediation problem that cannot be solved by a regulatory writing team working in isolation. The laboratory work required to close Ph. Eur. 5.1.7 testing gaps, qualify a mechanistically-linked potency assay, and document starting materials under Annex I takes time, batch material, and analytical resources that are never available on the timeline that pre-submission discovery creates. The programs that maintain global development schedules are those that treat CBER and EMA CAT as two parallel regulatory frameworks requiring a shared CMC evidence base from IND-enabling studies forward — not two sequential submission projects built from the same package. The cost of dual-region CMC strategy at IND is a structured gap assessment and a modified testing plan; the cost at pre-BLA/pre-MAA is a clinical hold, a refused filing, or a comparability-driven delay that resets regulatory timelines by a year or more.

If your GT program plans both FDA and EMA submissions, can you identify today the specific document in your CMC package that addresses EU ATMP starting material requirements under Annex I of Directive 2001/83/EC, and whether your adventitious agent testing protocol includes Ph. Eur. 5.1.7 methods alongside your current FDA-aligned testing strategy?